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Abstract
We examined baseline data from the Systolic Blood Pressure Intervention Trial (SPRINT) to 
investigate whether medication adherence, measured by the Morisky Medication Adherence Scale 
(MMAS-8), was associated with systolic blood pressure (SBP), and whether MMAS-8 score and 
number of antihypertensive medications interacted in influencing SBP. 8,435 SPRINT participants 
were included: 21.2% had low adherence (MMAS-8: <6); 40.0% had medium adherence (6 to <8); 
and 38.8% had high adherence (8). SBP was <140 mmHg in 54.6%; 140 – 160 mmHg in 36.6%; 
and >160 mmHg in 8.8%. In multivariable regression, medium vs. low adherence weakly 
associated with lower SBP (OR: 1.17, CI: 1.04, 1.31). SPRINT eligibility criteria should be 
considered when interpreting results. Efforts to understand and enhance adherence are crucial to 
improve population health and using self-report instruments might be considered for predicting 
treatment adherence and response in future efficacy trials and for identifying patients for 
adherence support in clinical practice.
Keywords
Medication adherence; MMAS-8; systolic blood pressure; hypertension; clinical trial
INTRODUCTION
Medication non-adherence is a common problem and is one of the contributing factors to 
inadequate blood pressure control.1-5 A recent review of non-adherence also underscored the 
link to complications of hypertension and suggested routine screening.6 In addition, low 
medication adherence has been shown to be associated with adverse safety events.7 Several 
factors can influence patient medication adherence, such as complexity of regimen including 
number of medications; lack of knowledge about the disease; and medication side effects, 
including their impact on quality of life.8
The 8-item Morisky Medication Adherence Scale (MMAS-8) is an 8 question self-reported 
instrument that has proven to be a valid and reliable assessment tool for adherence. It 
provides information about situational factors that may act as barriers to medication 
adherence. Items on the scale reflect potential etiologies for non-adherent behavior, such as 
side effects and forgetfulness, with scores indicating low, medium or high adherence.9 The 
Systolic Blood Pressure Intervention Trial (SPRINT) included administration of the 
MMAS-8 at the baseline visit, and at the 12-month and 48-month followup.10 We performed 
a cross-sectional analysis of the SPRINT baseline data to investigate whether participants’ 
baseline MMAS-8 scores are associated with baseline systolic blood pressure (SBP) control 
prior to intervention, whether there is internal consistency of this association across groups 
defined by gender, ethnicity, and the SPRINT subgroups [chronic kidney disease (CKD) and 
Senior (≥75 year-old)], and whether there is an interaction between MMAS-8 score and 
number of antihypertensive medications in predicting SBP control.
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We conducted a cross-sectional examination of the SPRINT baseline data. The trial design 
has been described previously.10 In brief, SPRINT is a multicenter, randomized, controlled 
trial that compared cardiovascular outcomes, including myocardial infarction, acute 
coronary syndrome, stroke, heart failure, and cardiovascular death between groups with two 
different systolic blood pressure (SBP) goals: <120 versus <140 mm Hg. All participants 
were aged 50 years or older with SBP ≥ 130 mm Hg and with or at increased risk for 
cardiovascular disease (CVD). A full list of exclusion criteria has been published10; major 
exclusions included diabetes mellitus, 24-hour urine protein ≥ 1g/day, previous stroke, and 
adherence concerns. There were also specific inclusion criteria for SBP linked to the number 
of anti-hypertensive medications a participant was taking at baseline: 130-150 mmHg on 4 
medications, 130-160 mmHg on 3 medications, 130-170 mmHg on 2 medications, and 
130-180 mmHg on zero or 1 medication; patients on more than 4 antihypertensives were 
excluded.
Sample Population
We included in the analysis all participants enrolled in the SPRINT trial with the following 
available baseline data: demographics, comorbidities, Morisky Medication Adherence Scale 
(MMAS-8) score, number of medications at start of trial (baseline visit), and SBP. We 
excluded participants who were not taking any BP medications at baseline and those who 
had a missing or incomplete baseline MMAS-8.
Predictor Variable: Medication Adherence
Medication adherence was measured using the validated 8-item Morisky Medication 
Adherence Scale (MMAS-8), which is a self-reported questionnaire intended to measure 
medication adherence by providing information about behavioral and psychological factors 
that may act as barriers to medication adherence (Appendix). Items on the scale reflect 
potential reasons for non-adherent behavior, such as side effects, forgetfulness, and 
inconvenience. In the present study, participants were asked about medication adherence to 
anti-hypertensive agents prior to the SPRINT trial randomization. The MMAS-8 is scored as 
an ordinal measure with scores ranging from 0 to 8. It is categorized with a score of <6 
indicating “low adherence”, 6 to <8 “medium adherence,” and 8 “high adherence” based on 
previously published definitions.9
Primary Outcome: Systolic Blood Pressure Control
The primary outcome of interest was SBP control at baseline. Analyses were performed with 
SBP control as an ordinal categorical variable: SBP <140 mm Hg (controlled), SBP 140-160 
mm Hg, and SBP >160 mm Hg based on current guidelines.11-13 As outlined in the SPRINT 
design, all blood pressure data were collected using an OMRON blood pressure cuff (Model 
907XL, Omron Healthcare, Lake Forest, IL), by trained research coordinators. Three blood 
pressures were collected after the participant was sitting quietly alone and unobserved for 5 
minutes and were averaged.10
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Covariates were selected a priori on the basis of clinical significance and included gender, 
race, ethnicity, age (≥75 years old versus <75 years old), education level, and comorbidities 
that might affect either SBP or its management: atrial fibrillation/flutter; heart attack; 
congestive heart failure; peripheral vascular disease; total number of comorbidities; number 
of hypertension medications; CVD history; CKD; and tobacco use.
Statistical Analysis
Descriptive statistics for the sample were presented as frequencies and percentages or means 
and standard deviations. Participant characteristics were reported for the three levels of the 
MMAS-8: low, medium, and high – using the Chi-square or Fisher's Exact test for 
categorical variables and analysis of variance for continuous variables. Participant 
characteristics were similarly reported for the three levels of SBP control, along with their 
bivariate associations. Unadjusted and adjusted analyses using ordinal logistic regression 
models were used to produce odds ratios, 95% confidence intervals, and p-values, describing 
the relationship between MMAS-8 score category and SBP control. The score test for the 
proportional odds assumption was non-significant, indicating that the ordinal logistic model 
was appropriate.
In addition, interaction effects between number of medications, senior subgroup (≥75 years 
vs <75 years), race/ethnicity, and CKD, each with MMAS-8 score, on SBP control as the 
outcome were assessed using the Wald Chi-square test. As none of the interaction effects 
reached a level of statistical significance (p <0.1), all interaction terms were removed and the 
final adjusted model included only main effects. All analyses were performed using SAS 
version 9.4 (Cary, NC), and a 2 sided p-value of <0.05 was considered statistically 
significant.
RESULTS
There were 8,435 participants who met criteria for inclusion from the SPRINT trial 
database, from a total 9,361 included in the SPRINT trial. Of the 926 (9.9%) excluded 
individuals, 861 were not taking any BP medication at baseline and the remainder, 65, had a 
missing or incomplete baseline MMAS-8.
Low Adherence was observed in 21.2% of participants (N=1788), while 40.0% (N=3372) 
had Medium Adherence and 38.8% (N=3275) had High Adherence. Participants were 
predominantly male (63.4%), less than age 75 years (71.1%), Non-Hispanic White (56.8%), 
and with at least some post high school education (73.9%) (Table 1). Higher adherence was 
more common among men, participants aged ≥ 75 years, and those with higher levels of 
education, atrial fibrillation, CVD, and CKD. Higher adherence was less common among 
African Americans and current cigarette smokers. Participants who reported higher 
adherence reported a greater number of physical comorbidities, and a lower number of 
mental health comorbidities. The number of blood pressure lowering medications was not 
associated with adherence (Table 1).
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Blood pressure was controlled (baseline SBP < 140 mmHg) in 54.6% of participants 
(N=4,606); 36.6% (N=3,087) had baseline SBP 140 –160 mmHg; and 8.8% (N=742) had 
SBP > 160 mmHg (Table 2). Blood pressure control was more common among those 
reporting higher adherence and those taking more blood pressure lowering medications. 
Blood pressure control was also more common among men, those with greater education, 
and with history of heart attack. Participants with controlled blood pressure reported a 
greater number of mental health comorbidities (Table 2).
Baseline blood pressure lowering medication use in the 8435 participants prescribed at least 
one antihypertensive medication, overall and by adherence status, may be found in Table S1. 
The number of other concurrent medications (non-antihypertensive) was also assessed by 
adherence status: Overall (3.65 ± 2.7), Low (3.25 ± 2.7); Medium (3.74 ± 2.8); High (3.79 
± 2.8) (p<.0001).
In unadjusted analysis, there was a statistically significant association between better 
adherence and better blood pressure control (Table 2). With multivariable adjustment, this 
relationship persisted. Compared to participants with Low Adherence, those with Medium 
but not High Adherence were more likely to have SBP <140 mmHg (OR: 1.17, 95% CI: 
1.04, 1.31 and 1.10, CI: 0.98, 1.24, respectively, Table 3). Women, Seniors, and participants 
with less education or a history of heart failure had less well controlled blood pressure. 
Participants taking more blood pressure lowering medications, and those with a history of 
heart attack or more mental health comorbidities had better blood pressure control.
The interaction between the MMAS-8 adherence levels and the number of blood pressure 
lowering medications on SBP control was assessed and found to be non-significant 
(p=0.3220). Interaction effects of MMAS levels of adherence with gender, age (Senior 
subgroup), race/ethnicity, and chronic kidney disease were tested. None reached significance 
at p<0.05 (interaction p-values ranging from 0.10 to 0.66).
DISCUSSION
The aim of this study was to determine whether medication adherence as measured by 
MMAS-8 scores at baseline was associated with baseline SBP control and whether there was 
internal consistency of this association across groups defined by gender, race/ethnicity, and 
the SPRINT subgroups: CKD and Senior (age ≥ 75 years). A second aim was to evaluate 
whether there was a significant interaction between MMAS-8 scores and number of 
antihypertensive medications in their associations with SBP control. We hypothesized that 
there would be a significant association between adherence and SBP control, and that in 
patients taking a greater number of antihypertensive medications, the MMAS-8 score might 
be less strongly associated with SBP control. Whereas we observed associations between 
blood pressure control and both adherence and the number of blood pressure lowering 
medications, the hypothesized interaction was not observed. This finding is in contrast to 
studies that have found worse adherence and resultant blood pressure control in those taking 
greater numbers of medications.6, 14
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Assessment of medication adherence is difficult. Direct methods include urine and blood 
assays of medication metabolites, as well as physical observation. The former method is 
limited due to availability, cost constraints, and protocol issues making it impractical in 
long-term studies as well as clinical practice, while the latter may be prohibitively time and 
cost intensive.15-17 Indirect methods include self-report, pill counts, prescription refill rates, 
and electronic monitoring – all of which require time and resources.18-20 Of the 
aforementioned, self-reporting is the most convenient, and therefore most commonly used 
method. The MMAS-8 has been deemed valid as an assessment tool which is focused on 
behavioral determinants of adherence to antihypertensive regimens, and is a commonly 
utilized instrument.21-24 It is a parsimonious set of items which measure both unintentional 
and intentional reasons for non-adherence. In addition, a recent study examining the validity 
and reliability of antihypertensive adherence questionnaires deemed the MMAS-8 to be the 
most effective in terms of “sensitivity, specificity, positive predictive value, and negative 
predictive value, while maintaining acceptable validity and reliability”.21 The latter was 
defined with use of Cronbach's alpha, a frequently used estimate of the reliability of 
questionnaires, with “excellent” results defined by a value of ≥ 0.9, “good” 0.9 > α ≥ 0.8, 
“acceptable” 0.8 > α ≥ 0.7, and 0.5 > α “unacceptable”.25 For the MMAS-8, Cronbach's 
alpha was calculated to be 0.83.21
We found that better medication adherence as measured by MMAS-8 was weakly associated 
with better baseline SBP control prior to intervention in SPRINT. Better blood pressure 
control was more common in the Medium Adherence group but was only marginally more 
common in the High Adherence group than in the Low Adherence group. There was no 
significant interaction between MMAS-8 and gender, race/ethnicity, and the SPRINT 
subgroups: CKD and Senior (age ≥ 75 years), in associations with SBP control. In addition, 
there was no significant interaction between MMAS-8 and the number of antihypertensive 
medications in their associations with SBP control. Regarding the latter finding, it is 
important to consider the following factors. Patients selected for participation in SPRINT did 
not represent a random sample with respect to SBP and anti-hypertensive medications. 
Whereas the baseline SBP values were not constrained in SPRINT, the eligibility criterion 
for SBP at screening was 130 to 180. Furthermore, those with higher baseline BP were 
excluded unless the number of antihypertensive medications being taken at the time of 
screening was relatively low. Those with SBP between 170 and 180 mm Hg could have been 
taking only 1 hypertension medication, those between 160-170 mm Hg up to 2 medications, 
and those between 150-160 mm Hg up to 3 medications; while those with SBP between 
130-150 mm Hg could have been taking up to 4 hypertension medications. 10 Also excluded 
were those with history of poor adherence with medications or clinic visits, and those with 
medical, psychiatric or behavioral factors that in the opinion of the principal investigator 
might interfere with study participation or ability to adhere to the intervention program. 
Taken together, such conditions could be expected to weaken the ability to observe a 
relationship between medication adherence, number of antihypertensive medications, and 
SBP control in SPRINT. Nevertheless, these results add to the understanding of 
antihypertensive medication adherence and its link to SBP control.
Certain limitations are notable. SPRINT was a randomized, controlled, open-label trial 
conducted at 102 sites throughout the U.S. and Puerto Rico.10 This large diverse cohort of 
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9,361 individuals includes 36% female and 42% non-white, which is enriched with 2636 
participants aged ≥75 years and 2646 with CKD. SPRINT was not designed to test the 
relationship between medication adherence and BP control. Inclusion and exclusion criteria 
identified a trial population to ensure adequate event rates for statistical power, provide 
maximum generalizability, safety, and protocol implementation; these eligibility 
requirements facilitated a population at high risk for the major trial endpoints. Also excluded 
were patients with diabetes, polycystic kidney disease, stroke, proteinuria in excess of 1g/
day, eGFR <20 mL/min/1.73m2, any organ transplant, those in nursing homes, those with 
clinical diagnosis of dementia at baseline, those with secondary hypertension, and baseline 
standing orthostatic hypotension of concern (one minute standing BP <110). 
Generalizability is compromised with respect to these excluded groups. Another limitation 
relates to use of survey data. Even though, as noted previously, the MMAS-8 has been 
judged valid and reliable, nevertheless, relevant factors that may influence the accuracy of 
the MMAS-8 include individuals’ tendencies for recall bias, overestimation of adherence, 
and pursuit of socially acceptable responses.9 It should be noted that the current study 
reflects baseline data collected prior to the SPRINT trial randomization. Thus, the closer 
personal attention and motivation that are intrinsic to participation in research would not 
have influenced these results. Options for monitoring medication adherence, including drug 
serum and urine metabolite levels, physical observation, electronic monitoring, pill counting, 
and pharmacy fill rates, are cumbersome and otherwise fraught with their own weaknesses.6 
We are aware that use of multiple measures of adherence may enhance validity; however, we 
judged that we did not have the resources required to incorporate other assessments of 
adherence at baseline in SPRINT. Selection bias must be considered, insofar as those 
individuals with history of poor adherence with medications or clinic visits, and those with 
medical, psychiatric or behavioral factors that in the opinion of the principal investigator 
might interfere with study participation or ability to adhere to the intervention program were 
excluded from participating in this trial. The latter would tend to constrain our variance in 
adherence, decreasing the likelihood of detecting associations. Finally, we noted that 
selection criteria for SPRINT did not allow for a representative population with respect to 
numbers of antihypertensive medications and SBP, a condition that could be expected to 
weaken the ability to detect a relationship between SBP control, number of antihypertensive 
medications, and medication adherence at baseline.
Higher medication adherence, assessed by MMAS-8, was weakly associated with better SBP 
control in SPRINT. SPRINT eligibility criteria should be considered when interpreting these 
findings: individuals with SBP <130 were excluded; likewise, the high end of the SBP range 
was constrained differentially by the number of baseline medications. These trial features 
restricted the range of SBP observed, reducing variation and hence power to detect an 
association of adherence with SBP control. Assessment of adherence is challenging in 
research and practice settings; nevertheless, we believe that efforts to understand and 
enhance adherence are critical to improve population health; use of parsimonious self-report 
instruments such as the MMAS-8 might be considered for predicting treatment adherence 
and response in future efficacy trials and for identifying patients for adherence support in 
clinical practice.
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Appendix
Appendix 1
Morisky Medication Adherence Scale as Included in the Sprint Trial.
Question Response Options
1. Do you sometimes forget to take your high blood pressure pills? Yes
No




3. Have you ever cut back or stopped taking your medication without telling your doctor because 
you felt worse when you took it?
Yes
No
4. When you travel or leave home, do you sometimes forget to bring along your medications? Yes
No
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5. Did you take your high blood pressure medicine yesterday? Yes
No




7. Do you ever feel hassled about sticking to your blood pressure treatment plan? Yes
No
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• Medication adherence was measured at baseline in SPRINT.
• Twenty-one percent had low, 40% had medium, and 39% had high 
adherence.
• Systolic blood pressure was <140 in 55%, 140–160 in 37%, and >160 
in 9%.
• Baseline adherence and systolic blood pressure were weakly 
associated.
• No interaction between adherence and number of antihypertensive 
meds on systolic blood pressure control.
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Table 1
Baseline Demographic and Personal Characteristics and their Association with the Morisky Medication 
Adherence Scale - mean ± SD or frequency (col %)








    Female 3086 704 (39.4) 1215 (36) 1167 (35.6)
    Male 5349 1084 (60.6) 2157 (64) 2108 (64.4)
Age <.0001
    ≥ 75 (Senior) 2430 346 (19.4) 994 (29.5) 1090 (33.3)
    < 75 6005 1442 (80.6) 2378 (70.5) 2185 (66.7)
Race/Ethnicity <.0001
    Non-Hispanic White 4799 723 (40.4) 1997 (59.2) 2079 (63.5)
    Black/African American 2574 816 (45.6) 988 (29.3) 770 (23.5)
    Hispanic 910 209 (11.7) 325 (9.6) 376 (11.5)
    Other 152 40 (2.2) 62 (1.8) 50 (1.5)
Education <.0001
    Less than High School 817 214 (12) 327 (9.7) 276 (8.4)
    High School Graduate/GED 1383 317 (17.7) 540 (16) 526 (16.1)
    Post High School 2988 690 (38.6) 1185 (35.1) 1113 (34)
    College Degree 3246 567 (31.7) 1320 (39.1) 1359 (41.5)
Atrial Fibrillation/Flutter (vs no) 719 117 (6.5) 283 (8.4) 319 (9.7) 0.0005
Heart Attack (vs no) 727 136 (7.6) 313 (9.3) 278 (8.5) 0.12
Congestive Heart Failure (vs no) 316 77 (4.3) 121 (3.6) 118 (3.6) 0.37
Peripheral Vascular Disease (vs no) 463 103 (5.8) 204 (6) 156 (4.8) 0.059
Number of Comorbidities
    Physical (out of 38) 4.5 ± 2.6 4.31 ± 2.6 4.55 ± 2.7 4.56 ± 2.6 0.0042
    Mental (out of 6) 0.4 ± 0.8 0.55 ± 1.0 0.38 ± 0.8 0.34 ± 0.7 <.0001
Number of HTN Medications 0.60
    1 2673 587 (32.8) 1050 (31.1) 1036 (31.6)
    2 3255 693 (38.8) 1302 (38.6) 1260 (38.5)
    >2 2405 484 (27.1) 979 (29) 942 (28.8)
CVD History (vs no) 1781 343 (19.2) 753 (22.3) 685 (20.9) 0.029
Chronic Kidney Disease (vs no) 2514 449 (25.1) 1044 (31) 1021 (31.2) <.0001
Tobacco use <.0001
    Never/Former 7378 1425 (79.7) 2995 (88.8) 2958 (90.3)
    Current 1050 360 (20.1) 376 (11.2) 314 (9.6)
Use of the ©MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. Morisky, 
ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA Fielding School of Public Health, 650 Charles E. Young Drive 
South, Los Angeles, CA 90095-1772..
*
P-value from Chi Square test or Fisher's Exact Test for categorical variables and simple logistic regression for continuous variables
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Table 2
Baseline Demographic and Personal Characteristics and their Association with Systolic Blood Pressure - mean 
± SD or frequency (row %)
Characteristic SBP<140 mmHg n=4604 
(54.6%)
SBP 140-160 mmHg n=3087 
(36.6%)




    Low Adherence 949 (53.1) 655 (36.6) 184 (10.3)
    Med Adherence 1894 (56.2) 1187 (35.2) 291 (8.6)
    High Adherence 1763 (53.8) 1245 (38.0) 267 (8.2)
Gender <.0001
    Female 1522 (49.3) 1196 (38.8) 368 (11.9)
    Male 3084 (57.7) 1891 (35.3) 374 (7.0)
Age <.0001
    ≥ 75 (Senior) 1154 (47.5) 1000 (41.2) 276 (11.4)
    < 75 3452 (57.5) 2087 (34.8) 466 (7.8)
Race/Ethnicity 0.47
    Non-Hispanic White 2646 (55.1) 1747 (36.4) 406 (8.5)
    Black/ African American 1408 (54.7) 926 (36.0) 240 (9.3)
    Hispanic 474 (52.1) 356 (39.1) 80 (8.8)
    Other 78 (51.3) 58 (38.2) 16 (10.5)
Education 0.021
    Less than High School 413 (50.6) 311 (38.1) 93 (11.4)
    High School Graduate/GED 754 (54.5) 499 (36.1) 130 (9.4)
    Post High School 1615 (54.1) 1112 (37.2) 261 (8.7)
    College Degree 1824 (56.2) 1164 (35.9) 258 (8.0)
Atrial Fibrillation/Flutter 386 (53.7) 270 (37.6) 63 (8.8) 0.86
Heart Attack 433 (59.6) 247 (34.0) 47 (6.5) 0.007
Congestive Heart Failure 164 (51.9) 117 (37.0) 35 (11.1) 0.30
Peripheral Vascular Disease 237(51.2) 181 (39.1) 45 (9.7) 0.30
Number of Comorbidities
    Physical (out of 38) 4.48 ± 2.6 4.53 ± 2.7 4.51 ± 2.6 0.54
    Mental (out of 6) 0.42 ± 0.9 0.39 ± 0.8 0.31 ± 0.7 0.0002
Number of HTN Medications 0.043
    1 1399 (52.3) 1038 (38.9) 236 (8.8)
    2 1826 (56.1) 1146 (35.2) 283 (8.7)
    >2 1326 (55.1) 862 (35.9) 217 (9.0)
CVD History 999 (56.1) 639 (35.9) 143 (8.0) 0.25
Chronic Kidney Disease 1378 (54.8) 899 (35.8) 237 (9.4) 0.28
Tobacco use 0.90
    Never/Former 4030 (54.6) 2702 (36.6) 646 (8.8)
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Characteristic SBP<140 mmHg n=4604 
(54.6%)
SBP 140-160 mmHg n=3087 
(36.6%)
SBP>160 mmHg n=742 
(8.8%) p-value
*
    Current 574 (54.7) 380 (36.2) 96 (9.1)
*
P-value from Chi Square test or Fisher's Exact Test for categorical variables and simple logistic regression for continuous variables
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Table 3
The Association between Better Systolic Blood Pressure Control and Medication Adherence While Adjusting 
for Demographic and Behavioral Risk Factors, Number of Hypertension Medication, and Comorbidities
Characteristic Adjusted Odds Ratio 95% Confidence Interval p-value
*
MMAS
    Low Adherence --- --- ---
    Med Adherence 1.166 (1.04, 1.31) 0.009
    High Adherence 1.100 (0.98, 1.24) 0.11
Gender
    Female 0.702 (0.64, 0.77) <.0001
    Male --- --- ---
Age
    ≥ 75 (Senior) 0.644 (0.58, 0.71) <.0001
    < 75 --- --- ---
Race/Ethnicity
    Non-Hispanic White --- --- ---
    Black/African American 1.019 (0.92, 1.13) 0.73
    Hispanic 0.926 (0.80, 1.07) 0.31
    Other 0.830 (0.60, 1.14) 0.25
Education
    Less than High School 0.816 (0.70, 0.96) 0.012
    High School Graduate/GED 0.930 (0.82, 1.06) 0.27
    Post High School 0.903 (0.82, 1.00) 0.048
    College Degree --- --- ---
Atrial Fibrillation/Flutter 0.998 (0.85, 1.17) 0.98
Heart Attack 1.244 (1.04, 1.49) 0.019
Congestive Heart Failure 0.779 (0.62, 0.98) 0.036
Peripheral Vascular Disease 0.867 (0.71, 1.05) 0.15
Number of Comorbidities
    Physical 1.007 (0.99, 1.03) 0.47
    Mental 1.078 (1.02, 1.14) 0.009
Number of Hypertension Medications
    1 --- --- ---
    2 1.150 (1.04, 1.27) 0.007
    >2 1.107 (0.99, 1.24) 0.072
CVD History 1.004 (0.89, 1.14) 0.95
Chronic Kidney Disease 1.095 (0.99, 1.21) 0.067
Tobacco use
    Never/Former --- --- ---













Haley et al. Page 16
Characteristic Adjusted Odds Ratio 95% Confidence Interval p-value
*
    Current 0.904 (0.79, 1.04) 0.14
*
P-value from ordinal logistic regression modeling
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